## **Factsheet**



### as of 30 Sep 2009

**Fund Description** 

### **DekaLux-MidCap TF A**

Equity Funds Europe ISIN LU0075131606

Benchmark: 1, 2 100% Dow Jones STOXX TMI Growth Mid Index (net total return in Euro)®

#### The fund invests in small and mid-cap European equities. Derivatives are generally not used. The investment objective is to generate a risk-adjusted outperformance of the benchmark. The fund manager relies to a large extent on in-house buy-side research for bottom-up selection of growth stocks. We believe that companies with the potential to outperform the market in the medium term can be identified through preliminary screening of a large investment universe, rigorous growth-oriented fundamental equity research, and close contact with company management. The fund manager is responsible for performance and has the final authority to make investment decisions. Risk management is an integral part of the investment process. The results of scenario analyses are used to create an adequate level of diversification and a sell discipline limits downside risk. Trades are executed by


| F  | und Facts                       |                   |
|----|---------------------------------|-------------------|
| R  | euters-Code                     | 986354X.DX        |
| В  | loomberg-Code                   | DEKAMID           |
| Fι | und Manager                     | Matthias Bussemer |
| Ν  | o. of Securities in Fund        | 241               |
| Fι | und Currency                    | EUR               |
| Fι | und Volume                      | 123.0 m EUR       |
| Lá | aunch Date                      | 03 Mar 1997       |
| Eı | nd of Fiscal Year               | 30 Sep            |
| D  | ividend Policy                  | Distribution      |
| А  | mount of Last Dividend          | 0.05 EUR          |
| D  | ate of Last Dividend            | 20 Nov 2008       |
| Ν  | AV per share                    | 37.67 EUR         |
| Τ. | I.S. (Taxable Income per Share) | 0.00 EUR          |
| St | tock-Related Profits (in %)     | 42.11             |
|    |                                 |                   |
|    |                                 |                   |


| Fund Fees   |              |
|---|--------------|
| Subscription Fee                                    | 0.00 %       |
| Management Fee <sup>3</sup>                         | 1.500 % p.a. |
| Distribution Fee                                    | 0.720 % p.a. |
| Custodian Bank Fee                                  | 0.100 % p.a. |
| Introduction of Performance-based Fee 4             | 01 May 2007  |
| Performance-based Fee ex post (fiscal year 2007/08) | 0.080 %      |
| TER (fiscal year 2007/08) 5                         | 2.490 %      |
| TER plus PF (fiscal year 2007/08) 5, 6              | 2.570 %      |

specialist traders in accordance with the principle of 'best execution'. Foreign currency exposure is not hedged.

| Fund Data                                     |        |
|---|--------|
| Risk Weight (in %) <sup>7</sup>               | 100.00 |
| Volatility according to MaH (in %) 8          | 33.16  |
| Foreign Currency Exposure (in %) <sup>9</sup> | 58.65  |
|   |        |

| Rating Information   |                                  |  |
|----------------------|----------------------------------|--|
| Feri Fonds Rating 10 | Morningstar Rating <sup>11</sup> |  |
| А                    | 000                              |  |





# **Factsheet**



## as of 30 Sep 2009

## **DekaLux-MidCap TF A**


Equity Funds Europe ISIN LU0075131606

Benchmark: 1, 2 100% Dow Jones STOXX TMI Growth Mid Index (net total return in Euro)®

| Largest Holdings      |                        |                |        | (in %) |
|-----------------------|------------------------|----------------|--------|--------|
| Security              | Sectors                | Country        | Aug 09 | Sep 09 |
| BASILEA PHARM.        | Health Care            | Switzerland    | 1.6    | 1.6    |
| SEADRILL LTD.         | Energy                 | Bermuda        | 1.4    | 1.5    |
| TEMENOS GROUP AG -NA- | Information Technology | Switzerland    | 1.4    | 1.5    |
| CAIRN EN.PLC          | Energy                 | United Kingdom | 1.3    | 1.4    |
| KUDELSKI SA           | Information Technology | Switzerland    | 1.4    | 1.3    |
| NOKIAN RENKAAT OYJ    | Consumer Discretionary | Finland        | 1.3    | 1.2    |
| TOMTOM N.V.           | Consumer Discretionary | Netherlands    | 1.0    | 1.1    |
| THROMBOGENICS N.V.    | Health Care            | Belgium        | 1.0    | 1.1    |

| Performance <sup>12</sup>         |       |      |       |       |      |                |       |
|-----------------------------------|-------|------|-------|-------|------|----------------|-------|
|                                   | YTD   | 1M   | 3M    | 6M    | 1Y   | 3Y             | 5Y    |
| Fund (in %) EUR                   | 47.78 | 6.65 | 20.20 | 55.98 | 4.96 | -4.72          | 68.25 |
| Fund p.a. (in %) EUR 13           |       |      |       |       | 4.96 | -1.60          | 10.97 |
| Benchmark (in %) EUR <sup>1</sup> | 37.30 | 4.89 | 16.41 | 41.40 | 0.18 | <b>-</b> 24.25 | 20.67 |
| Benchmark p.a. (in %) EUR 1, 13   |       |      |       |       | 0.18 | -8.84          | 3.83  |





| Risk Parameters    |                        |               |               |               |
|--------------------|------------------------|---------------|---------------|---------------|
|                    |                        | 1Y            | 3Y            | 5Y            |
| Tracking Error (%) | Fund                   | 7.6           | 8.3           | 8.2           |
| Information Ratio  | Fund                   | 0.66          | 0.92          | 0.81          |
| Correlation        | Fund                   | 0.98          | 0.96          | 0.95          |
| Alpha (%)          | Fund                   | 5.1           | 8.8           | 6.1           |
| Beta               | Fund                   | 1.07          | 1.13          | 1.14          |
| Max. Gain (%) 14   | Fund                   | 67.0          | 67.0          | 167.6         |
|                    | Benchmark <sup>1</sup> | 53.7          | 53.7          | 96.6          |
| Max. Loss (%) 14   | Fund                   | <b>-</b> 37.8 | <b>-</b> 61.8 | <b>-</b> 61.8 |
|                    | Benchmark <sup>1</sup> | -36.0         | <b>-</b> 59.5 | <b>-</b> 59.5 |
| Volatility (%) 15  | Fund                   | 35.0          | 28.1          | 24.3          |
|                    | Benchmark <sup>1</sup> | 32.0          | 23.9          | 20.1          |
| Sharpe Ratio 16    | Fund                   | 0.03          | negative      | 0.28          |
|                    | Benchmark <sup>1</sup> | negative      | negative      | 0.00          |

# **Factsheet**



### as of 30 Sep 2009

### **DekaLux-MidCap TF A**

Equity Funds Europe ISIN LU0075131606

Benchmark: 1, 2 100% Dow Jones STOXX TMI Growth Mid Index (net total return in Euro)®

| Fund Share Classes   |              |             |
|----------------------|--------------|-------------|
| Tranche              | ISIN         | Launch Date |
| DekaLux-MidCap TF A  | LU0075131606 | 03 Mar 1997 |
| DekaLux-MidCap TF T  | LU0265741370 | 02 Oct 2006 |
| DekaLux-MidCap F (T) | LU0342006888 | 04 Mar 2008 |

#### Deka International S.A.

5, rue des Labours, L-1912 Luxemburg

Licensors shall have any liability with respect thereto.

- 1 The adjusted benchmark shows the respective benchmark. The price calculation for the benchmark has been set at a time as close as possible to the time of price calculation for the fund. The benchmark may have changed in the past.

  The benchmark index only serves for informational purposes. The asset manager is under no obligation to replicate the index or match the
- performance of the index.

  The Dow Jones STOXX TMI Growth Mid Index (net total return in Euro)® is the intellectual property (including registered trademarks) of STOXX Limited, Zurich, Switzerland and/or Dow Jones & Company, Inc., a Delaware corporation, New York, USA, (the "Licensors"), which is used under license. The DekaLux-MidCap TF based on the Index is in no way sponsored, endorsed, sold or promoted by the Licensors and neither of the
- 3 The Management Fee includes a sales commission for funds issued in Germany.
- 4 Introduction of performance-based fee: 01 May 2007. The calculation methodology is: Up to 1/4 of the amount by which the fund outperforms its benchmark index on a gross-of-fee basis.
- <sup>5</sup> Total costs in per cent of the average fund volume of the past fiscal year. The Total Expense Ratio (TER) includes all fees related to the investment in the fund except the transaction fees and if applicable performance dependent fees.
- 6 TER plus Performance-based Fee
- 7 Risk weight as of 21 Sep 2009 in accordance with the credit risk standard method of the German Solvency Regulation.
- 8 Risk measure according to the "Minimum Requirements for the Trading Activities of Credit Institutions" (MaH).
- 9 Percentage of foreign currency exposure as of 21 Sep 2009 in accordance with the credit risk standard method of the German Solvency Regulation.
- 10 Rating as of 31 Aug 2009; see www.feri.de for further information
- 11 Rating as of 31 Aug 2009; see www.morningstar.de for further information
- 12 Calculated according to BVI methodology. Subscription fees were not taken into consideration. Source: DekaBank

#### Past performance is not a reliable indicator for future performance.

- 13 The annualized (p.a.) perforances are the average performances of the specified time period.
- 14 Maximum gain/loss in percent, based on daily performance without currency effects over the specified time period.
- 15 Volatility in % is calculated on the basis of weekly (for a track record of less than 3 years) or monthly (for a track record greater than 3 years) data.
- 16 The risk free rate is orientated to the three-month treasury rate. A negative Sharpe Ratio has no informative value.

This data was compiled carefully. However, we do not accept liability for incorrect data.

This information should not be used in lieu of a personal consultation with an investment advisor. The sales prospectus and the by law mandatory reports are the solely binding documents when acquiring Deka Investmentfunds. These are made available to you by DekaBank at 60625 Frankfurt or under www.deka.de

Notes: